
Scilex Holding Company – NASDAQ:SCLXW
Scilex Holding Company stock price today
Scilex Holding Company stock price monthly change
Scilex Holding Company stock price quarterly change
Scilex Holding Company stock price yearly change
Scilex Holding Company key metrics
Market Cap | 109.86M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.88 |
Revenue | 47.04M |
EBITDA | -102.63M |
Income | -107.95M |
Revenue Q/Q | 2.85% |
Revenue Y/Y | 12.53% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -218.17% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeScilex Holding Company stock price history
Scilex Holding Company stock forecast
Scilex Holding Company financial statements
Jun 2023 | 12.58M | -26.64M | -211.8% |
---|---|---|---|
Sep 2023 | 10.11M | -35.52M | -351.18% |
Dec 2023 | 13.46M | -21.4M | -158.97% |
Mar 2024 | 10.88M | -24.37M | -223.97% |
Jun 2023 | 126464000 | 116.04M | 91.76% |
---|---|---|---|
Sep 2023 | 80528000 | 243.19M | 302% |
Dec 2023 | 101309000 | 274.24M | 270.7% |
Mar 2024 | 91240000 | 281.02M | 308.01% |
Jun 2023 | -13.47M | -7.97K | 43.53M |
---|---|---|---|
Sep 2023 | 5.9M | -155K | -38.89M |
Dec 2023 | -5.36M | -166.17K | 8.26M |
Mar 2024 | 9.39M | -150K | -11.19M |
Scilex Holding Company alternative data
Aug 2023 | 76 |
---|---|
Sep 2023 | 76 |
Oct 2023 | 76 |
Nov 2023 | 76 |
Dec 2023 | 76 |
Jan 2024 | 109 |
Feb 2024 | 109 |
Mar 2024 | 105 |
Apr 2024 | 105 |
May 2024 | 105 |
Jun 2024 | 106 |
Jul 2024 | 106 |
Scilex Holding Company other data
Period | Buy | Sel |
---|---|---|
Nov 2022 | 1161776 | 0 |
Dec 2022 | 224841 | 0 |
-
What's the price of Scilex Holding Company stock today?
One share of Scilex Holding Company stock can currently be purchased for approximately $0.47.
-
When is Scilex Holding Company's next earnings date?
Unfortunately, Scilex Holding Company's (SCLXW) next earnings date is currently unknown.
-
Does Scilex Holding Company pay dividends?
No, Scilex Holding Company does not pay dividends.
-
How much money does Scilex Holding Company make?
Scilex Holding Company has a market capitalization of 109.86M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.9% to 46.74M US dollars.
-
What is Scilex Holding Company's stock symbol?
Scilex Holding Company is traded on the NASDAQ under the ticker symbol "SCLXW".
-
What is Scilex Holding Company's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Scilex Holding Company?
Shares of Scilex Holding Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Scilex Holding Company have?
As Jul 2024, Scilex Holding Company employs 106 workers, which is 1% more then previous quarter.
-
What is Scilex Holding Company's official website?
The official website for Scilex Holding Company is scilexholding.com.
-
Where are Scilex Holding Company's headquarters?
Scilex Holding Company is headquartered at 960 San Antonio Road, Palo Alto, CA.
-
How can i contact Scilex Holding Company?
Scilex Holding Company's mailing address is 960 San Antonio Road, Palo Alto, CA and company can be reached via phone at +65 05164310.
Scilex Holding Company company profile:

Scilex Holding Company
scilexholding.comNASDAQ
113
Drug Manufacturers - General
Healthcare
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Palo Alto, CA 94303
CIK: 0001820190
ISIN: US80880W1146
CUSIP: 80880W114